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Abstract
CD8+ tissue-resident memory T (TRM) cells provide frontline immunity in mucosal tissues. The 
mechanisms regulating CD8+ TRM maintenance, heterogeneity, and protective and pathological 
functions are largely elusive. Here, we identify a population of CD8+ TRM cells that is maintained 
by major histocompatibility complex class I (MHC-I) signaling, and CD80 and CD86 
costimulation after acute influenza infection. These TRM cells have both exhausted-like 
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phenotypes and memory features and provide heterologous immunity against secondary infection. 
PD-L1 blockade after the resolution of primary infection promotes the rejuvenation of these 
exhausted-like TRM cells, restoring protective immunity at the cost of promoting postinfection 
inflammatory and fibrotic sequelae. Thus, PD-1 serves to limit the pathogenic capacity of 
exhausted-like TRM cells at the memory phase. Our data indicate that TRM cell exhaustion is the 
result of a tissue-specific cellular adaptation that balances fibrotic sequelae with protective 
immunity.
INTRODUCTION
CD8+ memory T cells offer long-term protection against pathogen reinfection. In addition to 
circulating central and effector memory T cells, tissue-resident memory T (TRM) cells are a 
recently described memory subset that mainly reside in nonlymphoid organs and offer 
immediate protection by coordinating local innate and adaptive immunity (1, 2). TRM cells 
are phenotypically and transcriptionally distinct from circulating memory T cells. CD69, 
which antagonizes T cell recirculation and egress from tissues (3), is a key lineage-defining 
marker that distinguishes TRM cells and circulating memory T cells (4). In addition to CD69, 
a subset of CD8+ TRM cells also express the integrin molecule CD103, which enhances the 
tethering of TRM cells to epithelium via E-cadherin. Tissue-derived cues, particularly 
transforming growth factor–β (TGF-β), are critical for TRM cell development and/or 
maintenance (5). Although local antigen recognition in the tissue is not absolutely required 
for TRM cell formation, tissue antigen reencounter by effector CD8+ T cells after their 
priming in the draining lymphoid organs does facilitate optimal TRM cell development (6–8). 
Although recent studies have suggested that TRM cells are maintained independently of T 
cell receptor (TCR) signaling in the skin (9), much remains to be defined regarding the 
mechanisms regulating the maintenance and long-term survival of TRM cells in various 
tissues. Conventional circulating memory CD8+ T cells are maintained in a major 
histocompatibility complex class I (MHC-I)–independent manner; however, whether MHC-I 
and/or TCR signaling contributes to TRM cell maintenance and/or function after pathogen 
clearance is less clear.
In contrast to circulating memory T cells, TRM cells exhibit higher levels of expression of 
multiple effector cytokines and cytolytic molecules including interferon-γ (IFN-γ) and 
tumor necrosis factor–α (TNF-α) (10). The heightened expression of these molecules 
confers enhanced antimicrobial activity of TRM cells (10) but could potentially cause 
bystander inflammation and injury in the tissue. The mechanisms balancing the protective 
and potentially injurious effects of TRM cells during tissue homeostasis are largely 
unexplored. TRM cells express T cell inhibitory molecules, including programmed cell death 
protein 1 (PD-1) on their surface (11). It is conceivable that the expression of these 
molecules may restrict the capacity of TRM cells to promote tissue pathogenesis (11, 12).
Influenza infection in mice leads to the formation of TRM cells that confer resistance to 
reinfection, particularly in the lungs (13, 14). After influenza virus infection in the C57BL/6 
background, two major H-2Db restricted CD8+ T cell epitopes against nucleoprotein peptide 
366–374 (NP366–374) or polymerase peptide 224–233 (PA224–233) are displayed (15–17). 
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Previous studies have demonstrated that there is a marked difference in the 
immunodominance hierarchy between NP366–374 and PA224–233 T cells during primary and 
secondary CD8+ T cell responses. NP366–374 and PA224–233 epitope–specific CD8+ T cells 
appear in equivalent proportions during the primary CD8+ T cell responses, whereas 
NP366–374 T cells expand to a much greater proportion and dominate in secondary responses 
(16, 18–20). Antigen load, duration of antigen presentation, and differences in antigen-
presenting cells (APCs) were proposed to regulate the differential responses of NP and PA 
epitopes (15, 21, 22). Furthermore, NP366–374 and PA224–233 TRM cells exhibited distinct 
molecular signatures after secondary virus challenge (23). Of note, NP antigen was 
detectable in the lungs weeks after infectious viral clearance (24–26). How the chronic 
antigen reservoir regulates the phenotype, maintenance, and function of influenza-specific 
TRM cells has not been explored.
Here, we report that NP366–374 TRM cells in the lung receive chronic local TCR stimulation 
weeks after the clearance of infectious influenza virus. Consequently, these NP366–374 TRM 
cells adopt both conventional memory CD8+ T cell and exhausted-like features after 
influenza virus infection. Unlike conventional circulating memory CD8+ T cells that are 
maintained in an MHC-I–independent manner, these exhausted-like TRM cells are sustained 
by persistent TCR–peptide/ MHC-I (pMHC-I) signaling as the depletion of H-2Db at 28 
days post-infection (d.p.i.) selectively impairs the maintenance of these TRM cells. Likewise, 
B7-CD28 signaling blockade at the memory phase (starting at 21 d.p.i.) abrogates the 
persistence of exhausted-like TRM cells and consequently impairs TRM cell–mediated 
secondary heterologous immunity. In contrast, programmed death-ligand 1 (PD-L1) 
blockade at the memory phase promotes exhausted-like TRM cell expansion and 
rejuvenation. This augmentation of TRM cell function leads to enhanced secondary 
protection yet causes chronic tissue fibrotic sequelae after the resolution of the acute 
infection. Our data suggest that memory CD8+ T cells can adopt a tissue-specific cellular 
adaptation to balance fibrotic sequelae and secondary immunity.
RESULTS
Epitope-specific manifestation of an exhaustion gene signature in lung TRM cells after 
acute influenza infection
In C57BL/6 mice, influenza virus (A/PR8/34) infection is cleared from infected lungs 
around 10 d.p.i. (27–29). To assess the generation of TRM cells in the lung after influenza 
infection, we examined lung CD8+ TRM cell responses against NP366–374 and PA224–233 6 
weeks after infection. We used an in vivo antibody (Ab) labeling approach, in which 
fluorescently coupled CD45 Ab was administered intravenously to mice 5 min before tissue 
harvesting to distinguish lung- circulating (intravenous Ab+) and lung-resident (intravenous 
Ab−) CD8+ T cells (30). Lung-resident CD8+ NP366–374 and PA224–233 TRM cells expressed 
comparably higher levels of CD69 than the circulating NP366–374 and PA224–233 T cells (Fig. 
1A). Most of the PA224–233 TRM cells expressed CD103, but only a minor fraction of 
NP366–374 TRM cells was CD103+ (Fig. 1A and fig. S1, A and B). These data suggest that 
there may be epitope-specific heterogeneity between NP366–374 and PA224–233 TRM cells 
after acute influenza virus infection. To explore this idea, we performed RNA sequencing 
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(RNA-seq) analysis of sorted lung NP366–37 and PA224–233 TRM cells 6 weeks after 
infection. Consistent with the surface molecule expression, NP366–374 and PA224–233 TRM 
cells expressed comparable CD69, but Itgae (encoding CD103) was lower in NP366–37 TRM 
cells (Fig. 1B). NP366–374 TRM cells showed elevated expression of a number of coinhibitory 
molecules—including Pdcd1, Havcr2, Tigit, and Lag3 (Fig. 1B)—and transcription factors 
that are typically associated with exhausted T cells generated after chronic viral infection— 
such as Tox, Nfatc1, and Batf (Fig. 1B) (31–33). Gene set enrichment analysis (GSEA) 
demonstrated that NP366–374 TRM cells were positively enriched with the genes up-
regulated, and negatively enriched with the genes down- regulated, in exhausted CD8+ T 
cells after chronic viral infection (34), compared with PA224–233 TRM cells (Fig. 1C). To 
further profile the kinetics of the gene expression patterns of NP366–374 and PA224–23 CD8+ 
T cells, we sorted CD8+ T cells from spleens and lungs at effector (day 8) and memory (day 
38) stages and performed NanoString endogenous mRNA analysis on the expression of 560 
immunological genes in those effector or memory T cells without the need for amplification 
(Fig. 1D). We found that the immune gene expression patterns between NP366–374 and 
PA224–233 T cells at lung effector or splenic memory were quite similar(Fig. 1D). However, 
NP366–374 TRM cells and PA224–233 TRM cells had drastic differences in immune-associated 
gene expression patterns (Fig. 1D). Consistent with the RNA-seq data, NP366–374 TRM cells 
expressed higher levels of genes associated with T cell exhaustion compared with PA224–233 
TRM cells (Fig. 1E). Both NP366–374 and PA224–233 lung effector cells expressed higher 
exhaustion-associated genes than effector T cells in spleen, a feature of effector T cell 
“exhaustion” or “impairment” previously described during respiratory viral infections (Fig. 
1E) (35–38). Those exhausted genes were maintained or even further up-regulated in lung 
NP366–374 TRM cells at 38 d.p.i. (Fig. 1E). In contrast, those exhaustion-associated genes 
were generally down-regulated in PA224–233 TRM cells compared with day 8 effector T cells 
in the lungs (Fig. 1E). These observations suggest that there are distinct gene expression 
patterns in two epitope-specific polyclonal TRM cell populations and there exists an 
exhaustion-like gene pattern in a population of lung TRM cells after acute influenza infection 
reflective of those CD8+ T cells from chronic infections.
Exhausted-like NP366–374 TRM cells coexhibit exhaustion and memory features
On the basis of the gene expression data, we next examined the surface expression of 
inhibitory molecules. We first tracked the kinetics of PD-1 expression on lung NP366–374 and 
PA224–233 T effector or TRM cells over time. During the effector phase, NP366–374 and 
PA224–233 TRM cells had similar amounts of PD-1 expression (Fig. 2A). However, lung-
resident NP366–374 T cells maintained PD-1 expression that was lost on PA224–233 TRM cells 
at the memory stage (30 to 60 d.p.i.) (Fig. 2A). NP366–374 TRM cells also exhibited higher 
PD-1 expression than H2Kb-restricted T cells against the PB1 703–711 epitope (PB1703–711 
TRM cells) (fig. S1C) and ovalbumin (OVA)–specific OT-I TRM cells [after infection with 
recombinant influenza A PR8 expressing OVA323–339 epitope (PR8-OVA)] (fig. S1D), as 
well as higher than their splenic or lung-circulating counterparts (fig. S1E). Thus, NP366–374 
TRM cells appear to exhibit unique characteristics of high PD-1 expression at the memory 
stage.
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We next simultaneously evaluated the expression of multiple inhibitory receptors including 
PD-1, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-
activation gene 3(LAG-3),and T cell immunoreceptor with Ig and ITIM domains (TIGIT) on 
TRM cells. As previously reported (4, 11), both NP366–374 and PA224–233 TRM cells were 
PD-1+ cells (Fig. 2B). However, NP366–374 TRM cells expressed much higher PD-1 and a 
large proportion of the cells simultaneously expressed two or three more coinhibitory 
receptors on their cell surface revealed by Boolean gating (Fig. 2, B and C, and fig. S2, A to 
C). Incontrast, most of the PA224–233 TRM cells only expressed PD-1 (Fig. 2C and fig. S2C). 
PB1703–711 TRM cells also exhibited much lower TIM-3 expression compared with 
NP366–374 TRM cells (fig. S2D). Thus, compared with PA224–233 or PB1703–71 TRM cells, 
NP366–374 TRM cells coexpressed multiple coinhibitory receptors. Similar findings were also 
observed in influenza X31 virus infection, although to a lesser extent than influenza PR8 
infection (fig. S3, A to C). The coexpression of multiple coinhibitory receptors on NP366–374 
TRM cells suggests that these cells may have features similar to exhausted CD8+ T cells 
observed during chronic viral infection (39). Another hallmark of exhausted CD8+ T cells is 
diminished production of effector cytokines, particularly TNF-α, in response to antigenic 
stimulation (39, 40). We therefore examined lung TRM cell cytokine production after ex vivo 
peptide stimulation. NP366–37 TRM cells produced less IFN-γ and TNF-α compared with 
PA224–23 TRM cells, particularly when normalized to antigen-specific tetramer+ cells (Fig. 2, 
D and E, and fig. S3D), suggesting that NP366–374 TRM cells are less sensitive to TCR 
stimulation. These data indicate that NP366–374 TRM cells exhibit features of exhausted 
CD8+ T cells.
However, NP366–374 TRM cells expressed memory CD8+ T cell markers T cell factor 1 
(TCF-1) and CD127 (Fig. 2F) (41), similar to the levels found in PA224–233 TRM cells. 
Furthermore, we observed comparable levels of memory-associated genes between 
NP366–374 and PA224–23 TRM cells (Fig. 2G). TGF-β signaling has been shown to be 
important in the development of TRM cells in various tissues (5, 42). To address the role of 
TGF-β signaling in epitope-specific TRM cell development, we infected wild-type (WT) 
(Tgfbr2fl/fl) or dLck-cre Tgfbr2fl/fl (Tgfbr2Δdlck) mice with influenza virus. Tgfbr2 
deficiency did not impair CD8+ T cell priming in the secondary lymphoid organ at the 
effector phase (9 d.p.i.) (fig. S4A) but resulted in decreased frequency and numbers of both 
NP366–374 and PA224–233 TRM cells at 6 weeks after infection (Fig. 2, H and I, and fig. S4B). 
Impaired expression of CD103 on NP366–374 or PA224–233 TRM cells was also observed in 
the absence of TGF-β signaling (fig. S4C). These data suggest that similar to “conventional” 
PA224–233 TRM cells, NP366–374 TRM cells also require TGF-β signaling for their formation. 
A key feature of memory T cells is their ability to expand upon secondary antigenic 
challenge. Recent reports have revealed that TRM cells are able to proliferate in situ after 
reinfection (43, 44). We therefore examined whether NP366–374 TRM cells could respond to 
and proliferate in the lung upon heterologous influenza rechallenge. We blocked lymphocyte 
circulation 6 weeks after infection by the injection of FTY720 at 1 day before reinfection 
(fig. S4D). We then infected the mice with influenza A/X31 (H3N2), which differs in the 
surface proteins but shares internal proteins with influenza A/PR8, and examined TRM cell 
activation and proliferation 2 days after rechallenge (Fig. 2J). Influenza X31 reinfection 
stimulated CD69 up-regulation on lung NP366–374 TRM cells, suggesting that these cells 
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received and responded to antigenic signals invivo after secondary influenza X31 challenge 
(fig. S4E). There was a marked increase in TRM cell proliferation, specifically the NP366–374 
TRM cell population (Fig. 2J and fig. S4, F and G). These data cor-related well with previous 
findings that NP366–374 memory T cells dominate over PA224–233 memory T cells in the 
secondary expansion and provide heterologous immunity (15, 18, 19). Collectively, our 
results demonstrate that NP366–374 TRM cells exhibit both exhausted and memory T cell 
features. We termed this population of memory cells “exhausted-like TRM cells.”
Exhausted-like TRM cells receive persistent in situ TCR stimulation
We next sought to determine the underlying mechanisms regulating the formation and 
maintenance of exhausted-like TRM cells. Persistent TCR signaling is involved in the 
development of exhausted CD8+ T cells during chronic viral infections (39). We first 
explored whether NP366–374 TRM cells still received TCR signaling at the memory stage. 
Using Nur77-GFP transgenic mice that report on the activation of TCR signaling, we 
examined Nur77-GFP expression in TRM cells, and circulating and splenic memory T cell 
populations after infection with influenza PR8. A greater proportion of exhausted-like 
NP366–37 TRM cells expressed Nur77-GFP compared with PA224–233 TRM cells at 6 weeks 
after infection (Fig. 3A). NP366–374 TRM cells had higher Nur77-GFP expression than 
NP366–374 memory cells in the spleen or in the lung vasculature (Fig. 3A), suggesting that 
NP366–374 TRM cells may receive long-term TCR stimulation in situ. This is consistent with 
the fact that NP protein is more abundant than PA protein during influenza infection, which 
may lead to NP antigen persistence in the lung long after viral clearance (15, 25).
Residual antigen presentation in the draining mediastinal lymph nodes (mLN) by migratory 
dendritic cells can influence the phenotype and localization of memory T cells (24, 26). It is 
thus possible that NP366–374 CD8+ T cells may receive sustained and stronger antigen 
stimulation than PA224–233 memory T cells in the mLN and then migrate into the lung to 
develop into exhausted-like TRM cells. We injected FTY720 to WT mice daily starting at 3 
weeks after infection to block T cell migration (45) and then checked TRM cell phenotype at 
40 d.p.i. (Fig. 3B). Long-term FTY720 treatment suppressed T cell migration (fig. S5A). 
FTY720 treatment did not alter TRM cell Nur77-GFP expression or PD-1, TIM-3, CD69, or 
CD103 expression (Fig. 3, C and D), suggesting that T cell migration at the memory stage is 
probably not required for the development of exhausted-like TRM cells. These data also 
indicated that local TCR signaling may be responsible for the development of exhausted-like 
TRM cells. To further explore this idea, we wondered whether local inoculation of PA224–233 
peptide could lead to the induction of the exhausted-like phenotype in PA224–233 TRM cells. 
PA224–233 TRM cells acquired high levels of PD-1 expression after intranasal PA224–23 but 
not NP366–374 peptide administration at 35 d.p.i. (fig. S5, B and C). PA224–233 peptide 
stimulation also suppressed CD103 but not CD69 expression (fig. S5, D to F). These data 
suggest that lung in situ antigen presentation and resulting TCR signaling likely induce the 
development of epitope-specific exhausted-like TRM cells. Nur77-GFP+ cells had higher 
PD-1 expression (fig. S6A), suggesting that Nur77 (encoded by Nr4a1 gene) itself may be 
involved in the generation of exhausted-like TRM cells. To explore this idea, we created WT 
and Nr4a1−/− 1:1 mixed bone marrow chimeric mice and infected these mice with influenza 
PR8 (Fig. 3E). We found that Nur77 deficiency decreased PD-1 expression and frequencies 
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of exhausted-like NP366–37 TRM cells, but not those of PA224–233 TRM cells or splenic 
memory T cells (Fig. 3, E and F, and fig. S6, B to D), suggesting that TCR-induced Nur77 
expression is of specific relevance for the development of exhausted-like TRM cells.
Persistent MHC-I-dependent signaling drives the formation and maintenance of exhausted-
like TRM cells
We next sought to determine whether the exhaustion of NP366–37 TRM cells is dependent on 
NP antigen dose. We used an NP mutant influenza PR8 virus, in which the asparagine at the 
fifth position of the NP366–374 epitope was replaced with glutamine (N370Q). The N370Q 
mutation prevents the loading of NP366–374 peptide to MHC-I (46). This point mutation did 
not markedly affect influenza viral fitness and lung pathogenesis (fig. S7A) (46). We mixed 
a higher dose of this “mutant” NP virus [~200 plaque-forming units (pfu) per mouse] with 
lower doses of the “WT” NP virus (~40 or ~10 pfu). In this case, the initial WT NP epitope/
antigen amount is limited compared with a high-dose WT virus (~200 pfu) infection, but the 
viral-induced inflammation and disease progression are equivalent. We found that host 
morbidity after WT influenza PR8 virus and the mixed virus (NP mutant PR8/WT PR8) was 
similar (fig. S7A). However, PD-1 or TIM-3 expression was decreased on NP366–374 TRM 
cells from mixed virus–infected lungs, suggesting that antigen dose is a determinant of TRM 
cell exhaustion phenotype (fig. S7B). Influenza virus infection leads to the chronic 
deposition of antigen in the lung for about 2 to 3 months after infection (24, 26). Consistent 
with the timing of complete antigen clearance in the lung, we found that Nur77-GFP and 
inhibitory receptor expression on exhausted-like TRM cells were diminished at 120 d.p.i. 
(fig. S8).
The above data suggested that TRM cell exhaustion is likely caused by persistent antigen 
presentation in the respiratory tract. Thus, we sought to determine whether the development 
of exhausted-like NP366–374 TRM cells requires persistent MHC-I–dependent signaling. We 
bred MHC-I–deficient mice with the transgenic mice harboring H2db floxed allele 
(H2dbfl/fl). We then crossed the mice with Ubc-cre ERT2 transgenic mice 
(H2dbΔUbc-cre ERT2, KO), allowing tamoxifen-inducible ubiquitous depletion of H-2Db 
molecules (fig. S9A). Tamoxifen treatment before infection inhibited the development of 
influenza-specific CD8+ T cell responses in H2dbΔUbc-cre ERT2 mice (fig. S9, B to D), 
confirming the validity of the mouse model. We then infected control or H2dbΔUbc-cre ERT2 
mice with influenzaand depleted H-2Db around 4 weeks after infection (Fig. 4A). We 
examined TRM cell responses 2 weeks after H-2Db ablation. Tamoxifen injection caused 
H-2Db depletion in H2dbDUbc-cre ERT2 mice (fig. S9E). H-2Db ablation led to diminished 
expression of PD-1 and other coinhibitory receptors (including TIM-3 and TIGIT), 
specifically on exhausted-like NP366–374 TRM cells, but not on PA224–233 TRM cells (Fig. 4, 
B and C, and fig. S9F). H-2Db depletion decreased the frequencies and numbers of 
NP366–373 TRM cells but not those of PA224–233 TRM cells (Fig. 4, D and E). H-2Db ablation 
did not cause the loss of splenic NP366–374 or PA224–233 memory T cells (Fig. 4 D), whichis 
consistent with the notion that the maintenance of splenic memory T cells is MHC-I 
independent (47). H-2Db depletion resulted in increased CD103 expression but did not alter 
CD69 expression on exhausted-like TRM cells (Fig. 4, F and G, and fig. S9G).
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These data suggest that TCR–pMHC-I–dependent signaling at the memory phase is required 
for the development and maintenance of polyclonal exhausted-like TRM cells but not their 
splenic counterparts with TCRs against the same influenza epitope or local resident T cells 
with a TCR repertoire against the PA224–233 epitope. Consistent with this notion, NP366–374 
TRM cells gradually declined over time, whereas PA224–233 TRM cells or splenic NP366–374 
and PA224–233 memory cells were more stably maintained (fig. S10, A to C). To determine 
the consequence of exhausted-like NP366–374 TRM cell loss over time, we rechallenged the 
influenza PR8–infected mice with influenza X31 at 40 or 120 days after primary influenza 
PR8 infection in the presence of FTY720. Influenza X31 infection resulted in greater weight 
loss in those mice that were previously infected with influenza PR8 at 120 d.p.i. compared 
with those mice that were infected with influenza PR8 at 40 days prior, indicating that the 
loss of exhausted-like TRM cells may lead to impaired TRM cell–mediated protection against 
heterologous virus rechallenge (fig. S10D).
CD28 signaling is required for the maintenance of exhausted-like TRM cells
CD28 costimulation is required for naïve T cell expansion and memory T cell programming 
(48, 49), but its function in the maintenance of circulating or resident memory CD8+ T cells 
is not clear. Given that persistent pMHC-I–TCR signaling is required for the exhausted-like 
TRM cell maintenance, we sought to determine whether CD28 costimulation is required for 
the maintenance of those cells. In our NanoString gene expression data, CD28 was up-
regulated in exhausted-like NP366–374 TRM cells compared with PA224–233 TRM cells (Fig. 
5A). The gene expression data were confirmed by flow cytometry analysis of surface CD28 
protein on NP366–374 and PA224–233 TRM cells (Fig. 5B). To determine the function of CD28 
signaling in the development and/or maintenance of exhausted-like TRM cells after the 
resolution of primary infection, we blocked CD28-B7 interaction through the administration 
of anti-B7.1 (CD80) plus anti-B7.2 (CD86) (α-B7) starting at 21 d.p.i. (Fig. 5C). We then 
determined TRM phenotype and responses at 6 weeks after infection. Blockade of B7 
signaling decreased Nur77-GFP expression in NP366–374 TRM cells (fig. S11, A and B). B7 
Ab treatment also decreased PD-1 expression on NP366–374 TRM cells but not PA224–233 
TRM cells (Fig. 5C). Furthermore, B7 Ab treatment markedly decreased both the frequency 
and cell numbers of exhausted-like NP366–374 TRM cells but not those of PA224–233 TRM 
cells (Fig. 5, D and E). Blockade of CTLA-4, the other receptor for B7.1 and B7.2, did not 
impair NP366–374 TRM cell maintenance (fig. S11D), suggesting that the blockade of CD28 
signaling resulting from a-B7 treatment is responsible for the maintenance of exhausted-like 
NP366–374 TRM cells. Mechanistically, B7 blockade decreased NP366–374 TRM cell survival 
and proliferation as reflected by enhanced active caspase-3/7 activity and decreased KI-67 
staining, respectively, after a-B7 treatment (Fig. 5F and fig. S11E). These data suggest that 
persistent CD28 signaling at the memory stage is required for the maintenance of exhausted-
like TRM cells.
To explore whether impaired maintenance of exhausted-like TRM cells could decrease host 
resistance to heterologous immunity, we infected WT mice with influenza PR8 and then 
treated the mice with α-B7 as above. We injected the mice with FTY720 and subsequently 
rechallenged them with influenza X31 virus (1.2 × 104 pfu) at 6 weeks after infection (Fig. 
5G). Mice receiving B7 blockade lost significantly more weight compared with control mice 
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after influenza X31 infection (Fig. 5G). These data indicate that B7-CD28 costimulation is 
essential for the maintenance of exhausted-like TRM cells, which provide protective 
immunity against heterologous reinfection.
PD-L1 blockade promotes rejuvenation of exhausted-like TRM cells
Blockade of PD-1 and PD-L1 interaction promoted exhausted cell expansion and 
rejuvenation during chronic viral infection (40). We wondered whether the inhibition of PD-
L1–PD-1 interaction could rejuvenate exhausted-like TRM cells after the resolution of acute 
influenza virus infection. We infected the WT mice with influenza PR8 and treated the mice 
with a-PD-L1 from 21 to 37 d.p.i. (Fig. 6A). We then evaluated TRM cell responses at 40 or 
60 d.p.i. PD-L1 blockade increased both the frequency and cell numbers of exhausted-like 
NP366–37 TRM cells but not PA224–233 TRM cells or splenic NP366–374 and PA224–233 
memory T cells at 40 or 60 d.p.i. (Fig. 6, A to C, and fig. S12, A to C). Consistent with the 
enhanced maintenance of NP366–374 TRM cells, α-PD-L1 blockade enhanced their survival 
(Fig. 6D and fig. S12, D and E). In addition to treating the mice with α-PD-L1 starting at 21 
d.p.i., we performed additional experiments by injecting α-PD-L1 to the infected mice 
starting at 42 d.p.i. and then assessed TRM cell responses at 70 d.p.i. The blockade of PD-
L1–PD-1 interaction in this setting also increased the percentages and cell numbers of 
NP366–374 TRM cells but not PA224–233 TRM cells in the lung (fig. S12, F to H), suggesting 
that PD-L1 signaling inhibits the magnitude of NP366–374 TRM cell responses at the memory 
stage.
We next examined whether PD-L1 blockade affected TRM cell cytokine production. We 
found that PD-L1 blockade increased IFN-γ and TNF-α production by NP366–374 TRM cells 
(Fig. 6E and fig. S13, A to E) but had no effects on the IFN-γ and TNF-α production of 
PA224–233 TRM cells (fig. S13, F to K). This was true even when we normalized the 
percentages of IFN-γ and/or TNF-α production to antigen-specific tetramer+ cell numbers 
(Fig. 6E). Thus, PD-L1 blockade promoted exhausted-like TRM cell rejuvenation. In 
addition, PD-L1 blockade led to increased percentages of CD103+ cells and greater per-cell 
CD103 expression levels in exhausted-like TRM cells (Fig. 6, F and G) but did not affect 
CD103 expression on PA224–233 TRM cells (fig. S14, A and B). PD-L1 blockade did not alter 
CD69 expression on either NP366–374 or PA224–233 TRM cells (fig. S14C).
Because CD28 is required for the long-term maintenance of exhausted-like TRM cells and 
CD28 signaling was recently shown as a major target of PD-1 blockade (50, 51), we 
investigated whether the rejuvenation of exhausted-like TRM cells by PD-L1 blockade at the 
memory phase was dependent on CD28 signaling. We infected WT mice with influenza PR8 
and then administered control Ab, α-PD-L1, α-B7, or α-PD-L1 and α-B7 starting at 21 
d.p.i. Co-blockade of CD28 signaling abrogated the effects of PD-L1 blockade on 
exhausted-like NP366–374 TRM cell maintenance (Fig. 6H and fig. S15). Similarly, B7 
blockade decreased CD103 levels on exhausted-like TRM cells after a-PD-L1 blockade (Fig. 
6I). These data suggest that CD28 signaling is important for the effects of PD-L1 blockade 
on the maintenance and rejuvenation of exhausted-like TRM cells.
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Exhausted-like TRM cells balance protective immunity and fibrotic sequelae
Because exhausted-like NP366–374 TRM cells were important in TRM cell–mediated 
heterologous immunity and PD-L1 blockade at the memory phase increased cell numbers 
and function of these cells, we examined whether PD-L1 blockade increased TRM cell–
mediated immunity to influenza reinfection. We infected WT mice with influenza PR8 and 
blocked PD-L1 starting at 21 d.p.i. We then treated the mice with FTY720 and subsequently 
challenged the mice with a high dose of influenza X31 (2.4 × 104 pfu) at 6 weeks after 
infection. Mice with PD-L1 blockade lost significantly less weight than mice receiving 
immunoglobulin G control Ab (Fig. 7A). Similar results were obtained with mice receiving 
primary influenza X31 infection and PD-L1 blockade followed by secondary influenza PR8 
infection (fig. S16A). These data suggest that the rejuvenation of exhausted-like TRM cells 
enhances TRM cell–mediated heterologous protection against influenza reinfection.
TRM cells in the lung undergo enhanced cell death and wane over time after influenza 
infection (52, 53). This transient nature of influenza-induced lung TRM cells was proposed 
as a protective mechanism intended to prevent pathology, but this has not been proven (54). 
Because PD-L1 blockade promoted rejuvenation and maintenance in a population of TRM 
cells, we explored whether this could promote pathologic responses in the lung. PD-L1 
blockade from 21 to 42 d.p.i. increased tissue damage and inflammation at 60 d.p.i. (Fig. 7B 
and fig. S16B). PD-L1 blockade resulted in enhanced lung collagen deposition as revealed 
by Masson’s trichrome staining and hydroxyproline assay (surrogate measure of lung 
collagen content) (Fig. 7, B and C). The enhanced fibrotic sequelae after PD-L1 blockade 
were observed at 90 d.p.i. (fig. S16, C and D), indicating that PD-L1 blockade may cause 
tissue injury and persistent fibrotic sequelae after the resolution of acute influenza infection. 
The increased injurious and fibrotic responses after PD-L1 blockade were CD8+ T cell 
dependent as CD8+ T cell depletion abrogated the effects of PD-L1 blockade (Fig. 7D and 
fig. S17). These data suggest that TRM cell expansion and/or rejuvenation potentially 
contributed to pulmonary pathology and fibrosis.
To further explore this idea in human fibrotic lung disease, we stained the lungs from control 
or patients with idiopathic pulmonary fibrosis (IPF) with CD8, PD-1, and CD103. IPF lungs 
had increased tissue CD8+ T cells and CD8+ T cells coexpressing PD-1 or CD103 (Fig. 7, E 
and F), suggesting that patients with IPF have an enhanced TRM cell presence. Consistent 
with the notion, ITGAE (CD103) and PDCD1 (PD-1) genes were significantly up-regulated 
in the lungs of patients with interstitial lung diseases (ILDs, mostly IPF) in a large publicly 
available dataset (fig. S18). These data indicate that CD8+ TRM cells may be involved in the 
development and/or progress of human lung fibrosis. In summary, our data suggested that 
although exhausted-like properties render NP366–374 TRM cells less protective against 
reinfection, this TRM cell exhaustion prevents the host from developing overt injury resulting 
in fibrotic sequelae after acute influenza virus infection.
DISCUSSION
Memory CD8+ T cells are heterogeneous and display subsets of diversity with respect to 
their trafficking, metabolism, epigenetic regulation, and longevity (55). Here, we have 
described two types of TRM cell populations that arise from acute influenza virus infection. 
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The conventional PA224–233 TRM cells are relatively long-lived and maintained in a TCR–
pMHC-I–independent manner. An exhausted-like NP366–374 TRM cell population that 
exhibit both exhausted and memory features also develop from influenza virus infection. 
They are phenotypically exhausted but retain responsiveness in situ to secondary infections 
and also afford protection against heterotypic viruses with conserved CD8+ T cell epitopes. 
Compared with conventional TRM cells (for example, PA224–233 TRM cells), the maintenance 
of these exhausted-like TRM cells is dependent on persistent TCR–pMHC-I and CD28-B7 
costimulatory signals. These TRM cells have pathogenic and fibrogenic potential if their 
activities are unchecked after the release of PD-1–imposed suppression. These data indicate 
that polyclonal CD8+ memory T cells of different specificities may exhibit distinct 
transcriptional, phenotypic, and functional differences in the same tissue although they 
derive from the same infection. This type of epitope-specific variation and regulation of 
memory cells was observed previously in lymphoid organs (15).
The development of those exhausted-like features in NP366–374 TRM cells is likely due to the 
active adaptation of those cells to the local antigen containing lung environment even weeks 
after the clearance of the infectious virus. It is well documented that acute influenza virus 
infection leads to persistent influenza antigen deposition in the lung and continuous antigen 
presentation is observed in the draining lymph nodes executed via migratory lung dendritic 
cells (24, 26). Studies have suggested that the continuous antigen presentation may affect the 
quantity and quality of CD8+ memory T cells in secondary lymphoid organs (26). It is 
possible that exhausted-like NP366–374 TRM cells migrate continuously from the draining LN 
where they receive antigenic signaling. However, evidence presented here supports the idea 
that local antigen presentation in the lung, rather than in the draining lymph nodes, may be 
responsible for the development of exhausted-like TRM cells. First, compared with the 
resident NP366–374 TRM cells, NP366–374 cells in the lung vasculature were Nur77-GFP 
negative and express lower levels of PD-1, suggesting that exhausted-like NP366–374 TRM 
cells receive antigen presentation and CD28 signaling after the establishment of residence in 
the lung. Second, long-term blockade of T cell circulation via FTY720 treatment does not 
affect Nur77, PD-1, or other coinhibitory receptor expression on NP366–374 TRM cells, 
suggesting that T cell circulation at the memory stage is not required for the development of 
exhausted-like TRM cells. The fact that exhausted-like phenotypes are only observed in 
NP366–374 but not in PA224–233 TRM cells is probably due to the antigen dose and/or the 
duration of antigen presentation. Influenza virus contains a higher number of NP molecules 
(560 molecules per virion) than PA molecules (8 molecules per virion) (15). At later times 
after infection, when virally infected cells are cleared and the majority of antigen is in the 
form of cellular debris and neutralized virions, NP proteins would be present in greater 
amounts than PA (15). Therefore, the probability of processing and presentation of NP by 
lung APCs at the memory stage would be much higher than PA. Nevertheless, future studies 
are warranted to distinguish the roles of lung local antigen presentation versus draining LN 
peptide presentation in driving the development of exhausted-like TRM cells, to identify the 
exact cell types maintaining the residual antigen, and to determine the precise APC 
populations required for the maintenance of exhausted-like TRM cells.
The pathogenic cascade of lung fibrosis is thought to be initiated by repetitive microinjuries 
to the alveolar epithelium (56). Because of the enhanced expression of effector cytokines 
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and cytotoxic molecules, TRM cells could certainly be capable of initiating and/or 
amplifying epithelial injury if triggered by antigenic and/or rejuvenating signals such as 
PD-1 blockade. Whether TRM cell activation is involved in the development and/or 
exacerbations of human pulmonary fibrosis requires future studies. Influenza and other viral 
infections have been associated with both the development and exacerbation of established 
pulmonary fibrosis (57–60). It is tempting to speculate that the activation and/or 
rejuvenation of preexisting viral-specific exhausted-like TRM cells may contribute to the 
development of the lung injury and pathology. These ideas are supported by a recent report 
that PD-1–mediated inactivation of human CD8+ T cells alleviates lung fibrosis development 
in a humanized mouse model of bleomycin-induced pulmonary fibrosis (61). The degree of 
the pulmonary fibrosis observed in the influenza-infected mice after PD-L1 blockade is 
much milder than the acute lung fibrosis that develops after bleomycin inoculation. Whether 
these fibrotic sequelae could result in significant changes in lung function requires further 
studies.
Some limitations of this report are worth noting. In our study, we have only assessed TRM 
cell phenotypes for a limited number of CD8+ T cell epitopes after influenza infection, and it 
is possible that there is an even broader spectrum of TRM phenotypes. Furthermore, only 
respiratory mucosal tissue was examined in this study. Whether exhaustion-like TRM cells 
are present in the lungs or other mucosal tissues after infections with distinct pathogens 
warrants further studies. Nevertheless, TRM cell exhaustion observed in our study is likely an 
active adaptation of the cells delicately maintaining tissue immune memory while 
simultaneously preventing the development of excessive fibrotic sequelae. Potential 
activation of lung TRM cells may result in amplified inflammatory, injurious, and fibrotic 
signals contributing to the development and/or exacerbation of preexisting fibrotic 
respiratory diseases. It is thus important to identify strategies to specifically promote the 
protective function while, if possible, restraining the pathological function of TRM cells 
during vaccination and/or immunotherapies.
MATERIALS AND METHODS
Mouse and infection
WT C57BL/6, dLck-cre, Tgfbr2fl/fl, CD90.1 (Thy1.1), CD45.1, Ubc-creERT2, OT-I, and 
Nr4a1−/− mice were originally purchased from the Jackson Laboratory and bred in-house. 
Tgfbr2Δdlck mice were generated by breeding dLck-cre to Tgfbr2fl/fl mice. Control mice for 
Tgfbr2Δdlck mice are littermates without dLck-cre transgene (Tgfbr2fl/fl). To generate 
H2dbfl/fl transgenic mice, LoxP sites were inserted into a Db transgene. The transgene was 
introduced to C57BL/6 mice by the Mayo Clinic Transgenic Mouse Core (Rochester, MN). 
These animals were then backcrossed onto an MHC-I–deficient background until they 
lacked endogenous MHC-I. To generate H2dbΔUbc-creERT2 mice, MHC-I–deficient H2dbfl/fl 
transgenic mice were bred to Ubc-creERT2 transgenic mice to generate Ubc-creERT2/
H2dbfl/fl double transgenic mice on an MHC-I background (H2dbΔUbc-creERT2) (fig. S4A). 
Nur77-GFP reporter mice were a gift from G. Rajagopalan (Mayo Clinic) and bred in-house. 
All animal experiments were performed in animal housing facilities at the Indiana 
University School of Medicine (IUSM, Indianapolis, IN) or the Mayo Clinic (Rochester, 
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MN). Sex-matched and age-matched 9- to 12-week-old mice of both sexes were used in the 
experiments. All animal experiments were approved by the IUSM or the Mayo Clinic 
Institutional Animal Care and Use Committees. Influenza A/PR8/34 virus harboring point 
mutation that abrogates the binding of MHC-I to the NP366–374 peptide (PR8-NP mutant) 
was generated as described before (46). For influenza virus infection, influenza WT PR8 
virus (~200 pfu per mouse unless stated in the text in the primary infection and ~1 × 104 pfu 
per mouse in the secondary infection), PR8-NP mutant virus (~200 pfu per mouse), PR8 
expressing ovalbumin peptide (PR8-OVA) (~1200 pfu per mouse), or X31 (~800 pfu per 
mouse in the primary infection and ~1.2 × 104 or ~2.4 × 104 pfu per mouse in the secondary 
infection as indicated in the text) was diluted in fetal bovine serum (FBS)–free Dulbecco’s 
modified Eagle’s medium (Corning) on ice and inoculated in anesthetized mice through 
intranasal route as described before (28).
Human lung tissue sections
Archived human surgical lung biopsy specimens from individuals diagnosed with usual 
interstitial pneumonia (UIP) on biopsy (clinically IPF; n = 10) were obtained from the Mayo 
Clinic tissue bank. The diagnosis of UIP/IPF was based on standard criteria (62). Control 
lung tissue was obtained from surgical biopsy specimens acquired from patients undergoing 
lung biopsy for benign indications: primarily benign lung nodules. The control lung tissue 
samples used were from the lung tissue adjacent to the resected lung nodule. The control 
subjects (n = 10) did not have any evidence of interstitial lung diseases. The use of human 
lung tissue in this study was approved by the Mayo Clinic Institutional Review Board 
committee (protocol number 18–004030).
Immunofluorescence staining
Staining for two groups of combination of either CD8/CD103 or CD8/PD-1 was performed 
on formalin-fixed paraffin-embedded (FFPE) lung tissue slides. FFPE slides were 
deparaffinized in CitriSolv for 30 min and then immersed in alcohol series from 100, 95, 85, 
and 75% to distill H2O for 5 min each for tissue hydration. For antigen retrieval, hydrated 
slides were steamed for 20 min in 1 mM EDTA. The slides were then blocked with 10% 
normal goat serum phosphate-buffered saline (PBS) for 30 min at room temperature (RT) 
and then were incubated with either rabbit anti-CD103 (Abcam) or rabbit anti–PD-1 (Cell 
Signaling) overnight at 4°C.8After rinsing in 0.1% PBST (PBS with Tween 20) solution, the 
slides were incubated with Alexa Fluor 488–conjugated goat anti-rabbit secondary Ab (Life 
Technologies). After rinsing with 0.1% PBST, the slides were then incubated with Alexa 
Fluor 647–conjugated mouse anti- CD8 (BioLegend) for 60 min at RT. After stringent 
washing in 0.1% PBST, slides were aired before mounting with 4’,6-diamidino-2- 
phenylindole for nuclei counterstain. Tissue staining for the Ab mixture was reviewed and 
representative images were captured in Olympus cellSens Dimension system. Fifteen 
representative image fields were captured for each patient for quantification purposes.
RNA-seq and data analysis
Total RNA was isolated from sorted pooled NP366–374 or PA224–233 TRM population from 16 
mice (Qiagen). High-quality total RNA was used to generate the RNA-seq library. cDNA 
synthesis, end-repair, A-base addition, and ligation of the Illumina indexed adapters were 
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performed according to the TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA). 
The concentration and size distribution of the completed libraries were determined using an 
Agilent Bioanalyzer DNA 1000 chip (Santa Clara, CA) and Qubit fluorometry (Invitrogen, 
Carlsbad, CA). Paired-end libraries were sequenced on an Illumina HiSeq 4000 following 
Illumina’s standard protocol using the Illumina cBot and HiSeq 3000/4000 PE Cluster Kit. 
Base calling was performed using Illumina’s Real-Time Analysis (RTA) software (version 
2.5.2). Paired-end RNA-seq reads were aligned to the mouse reference genome (GRCm38/
mm10) using RNA-seq spliced read mapper Tophat2 (v2.1.1) (63). Pre- and post-alignment 
quality controls, gene level raw read count, and normalized read count (i.e., FPKM) were 
performed using RSeQC package (v2.3.6) with the NCBI mouse RefSeq gene model (64). 
We further calculated the logFC (fold change) by dividing FPKMNP/FPKMPA with 
additional restrictions on FPKM values as min (FPKMNP, FPKMPA) > 0 and max 
(FPKMNP, FPKMPA) > 5, and genes were sorted by logFC for GSEA analysis (http://
www.broadinstitute.org/gsea/). Gene lists of up-regulated and down-regulated genes in 
exhausted CD8+ T cells during chronic viral infection (compared with memory CD8+ T cells 
in acute viral infection) are adapted from GSE9650 (34). RNA-seq data were deposited in 
Gene Expression Omnibus (GEO) database (GEO number: GSE115786).
Hydroxyproline assay
Lung tissue was hydrolyzed in 1 ml of 6 M HCl at 95°C overnight. The hydrolysate was 
cooled down to RT and centrifuged for 10 min at 13,000g. The black particles on the surface 
of the hydrolysate were removed by vacuum sucking. Two and a half microliters of each 
sample was added to an indicated well of assay plate. Hydroxyproline standard solution was 
purchased from Sigma-Aldrich. Standard solution (1 mg/ml) was diluted 10 times, and 0, 2, 
4, 6, 8, and 10 ml of diluted standard solution were added into different wells in the assay 
plate for generation of standard curve. Then, the assay plate was placed in a 60°C oven to 
dry samples. One hundred microliters of freshly made chloramine-T solution (2.0 ml of n-
propanol, 0.282 g of chloramine-T, and 2.0 ml of H2O in 20 ml of citrate acetate buffer) was 
added into each well, and the mixture was incubated at RT for 20 min. Then, 100 ml of fresh 
Ehrlich solution (4.5 g of 4-dimethylaminobenzaldehyde in 18.6 ml of n-propanol and 7.8 
ml of perchloric acid) was added into each well. After that, the assay plate was placed at a 
60°C oven for 60 min before reading at 560-nm wavelength in a Thermax plate reader.
Intravascular CD8+ T cell labeling
Mice were injected intravenously with 1.5 mg of anti-CD45 diluted in 200 μl of sterile PBS 
as previously described (30). Mice were euthanized, and tissues were collected 5 min after 
injection of the intravenous Ab. Tissues were dissociated in 37°C for 30 min with 
gentleMACS (Miltenyi Biotec). Lung-circulating CD8+ are defined by intravenous Ab+, and 
lung-resident CD8+ are defined by intravenous Ab−.
OTI cell transfer
One million splenocytes from Thy1.1+ OTI mice were transferred into WT (Thy1.2+) 
congenic mice. Then, the mice were infected with PR8-OVA virus 24 hours later. At 6 weeks 
after infection, mice were injected with intravenous CD8• Ab, and lungs were collected for 
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TRM analysis. TRM phenotype of transferred OTI cells and endogenous NP366–374 or 
PA224–233 populations were based on Thy1.1 and Thy1.2 staining separation.
Flow cytometry analysis
Fluorescence-activated cell sorting (FACS) Abs were primarily purchased from BioLegend, 
BD Biosciences, or eBioscience. H-2Db Ab was purchased from Accurate Chem. The clone 
numbers of those Abs are as follows: CD8α(53–6.7), CD8β(YTS156.7.7), CD45(30-F11), 
CD45.1(A20), CD90.1(OX-7), CD90.2(53–2.1), PD-1(29F.1A12), TIM-3 (RMT3–23), 
Lag-3(C9B7W), TIGIT(1G9), CD103(2E7), CD69(H1.2F3), CD49a(TS2/7), 
CD127(A7R34), TCF-1(7F11A10), IFN-γ(XMG1.2), TNF(MP6-XT22), KI-67(SolA15), 
and H-2Db(B22–249.R1). The dilution of surface staining Abs was 1:200, and dilution of 
intracellular staining Abs was 1:100. H-2Db-NP366–374 and H-2Db-PA224–2 tetramers were 
from the National Institutes of Health tetramer facility. After Ab staining, cells were 
acquired through an 11-color Attune NxT system (Life Technologies). Data were then 
analyzed by FlowJo software (Tree Star).
Intracelluar staining
Cell suspensions were stained with the indicated surface marker, and staining was performed 
at 4°C for 30 min. Cells were washed twice with FACS buffer (PBS, 2 mM EDTA, 2% FBS, 
and 0.09% sodium azide) before fixation and permeabilization with either Perm Fix and 
Perm Wash (BD Bioscience, for cytokine staining) or the Foxp3 transcription factor staining 
buffer set (eBioscience, for KI-67 and TCF-1 staining) for 1 hour at RT in the dark. Cells 
were washed twice with perm wash (BD Bioscience or eBioscience); stained with Abs 
against TCF-1, KI-67, IFN-γ, and TNF for at least 30 min at RT; and washed twice with 
perm wash before flow cytometry acquisition (29).
Apoptotic cell detection
CellEvent Caspase-3/7 Green Flow Cytometry Assay Kit (Life Technologies) was used to 
detect active caspase activity inside the cells. Lung cells were incubated with CellEvent 
Caspase-3/7 green detection reagent for 25 min at 37°C as described in the manual. Annexin 
V Apoptosis Detection Kit (BioLegend) was used to detect phosphatidylserine on apoptotic 
cell surface. Lung cells were stained with annexin V and 7-aminoactinomycin D (7-AAD) 
for 15 min at RT according to the manual.
Tamoxifen treatment
To induce gene recombination in H2dbΔUbc-creERT2 mice, tamoxifen (Sigma-Aldrich) was 
dissolved in warm sunflower oil (Sigma-Aldrich) and administered via daily intraperitoneal 
injection for six consecutive times. Each application was 2 mg per mouse at a concentration 
of 20 mg/ml.
FTY720 treatment
For the influenza rechallenge experiment, mice were treated daily with FTY720 (1 mg/kg) 
by intraperitoneal injection starting at 1 day before rechallenge. For the chronic blockade of 
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memory T cell migration, mice were treated daily with FTY720 (1 mg/kg) starting at 21 
d.p.i. until 40 d.p.i., when mice were euthanized for TRM analysis.
Ab depletion and blockade in vivo
Anti-CD8, anti–PD-L1, anti-B7.1, anti-B7.2, and control Abs were purchased from Bio X 
Cell. For PD-L1 or CTLA-4 blockade experiments, WT B6 mice were infected with 
influenza and received intraperitoneal injection of control or blocking Abs at a dose of 500 
μg per mouse for the first time at 21 d.p.i. Mice then received intraperitoneal injection of 
Abs every 4 days (250 mg per mouse) thereafter. For B7 blockade experiments, WT B6 mice 
were infected with influenza and received anti-B7.1 (200 μg per mouse) and anti-B7.2 (200 
μg per mouse) treatment every 3 days starting at 21 d.p.i. or as stated in the text. For CD8 T 
cell depletion, mice received intraperitoneal injection of 400 μg per mouse once a week 
starting at 21 d.p.i.
Bone marrow chimera
To generate WT and Nr4a1−/− mixed bone marrow chimera, we injected CD45.1 mice with 
Busulfan (Sigma) at 100 mg/kg for four consecutive days. Mice were then reconstituted with 
Thy1.1+ WT bone marrow cells mixed with Thy1.2+ Nr4a1−/− bone marrow cells (1:1 ratio). 
Mice were rested for 6 weeks before infection with influenza. At 6 weeks after infection, 
mice were euthanized for the analysis of TRM. WT CD8+ T cells are identified as 
CD8+CD45.1−CD45.2+Thy1.1+ Thy1.2−, and Nr4a1−/− CD8+ T cells are identified as 
CD8+CD45.1− CD45.2+Thy1.1−Thy1.2+.
Peptide restimulation in vitro
Lung tissues were dissociated with gentleMACS (Miltenyi). Cell suspensions were 
restimulated with NP366–374 or PA224–233 peptide (100 ng/ml) (AnaSpec) for 5 hours in the 
presence of GolgiStop (BD Biosciences) (65). After restimulation, cells were first stained 
with surface markers and then were fixed and permeabilized using Perm Fix/Wash kits as 
described in the protocol.
Peptide inoculation in vivo
WT mice were infected with influenza PR8. At 35 d.p.i., mice were intranasally inoculated 
with PBS, PA224–233 peptide (10 μg per mouse), or NP366–374 peptide (10 μg per mouse) 
(AnaSpec) dissolved in PBS. At 37 d.p.i., mice were injected with intravenous CD8β Ab, 
and lungs were collected for TRM phenotype analysis.
Lung histopathology
After euthanasia, mice were perfused with PBS (10 ml) via the right ventricle. 
Paraformaldehyde (10%) (PF) was then gently instilled into the lung and left inflated for 1 
min before excising and moving the lobe to 10% PF for 48 hours followed by transfer to 
ethanol (70%). Samples were shipped to the Mayo Clinic Histology Core Lab (Scottsdale, 
AZ) where they were embedded in paraffin, and 5-mm sections were cut for hematoxylin 
and eosin and Masson’s trichrome stain.Slideswere then digitallyscannedbytheMayo 
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ClinicPathology Research Core (Rochester, MN) at 400× resolution with the Aperio system 
(Leica).
NanoString analysis
Total RNA from sorted T cell populations (n = 4 to 12 mice per group) was extracted with 
mini RNA Kit (Qiagen). Equal amounts of total RNA from different cells were used for the 
assay. Hybridization reaction was established by following the instruction of the 
manufacturer. Aliquots of Reporter CodeSet and Capture ProbeSet were thawed at RT. Then, 
a master mix was created by adding 70 μl of hybridization buffer to the tube containing the 
reporter codeset. Eight microliters of this master mix was added to each of the tubes for 
different samples; 5 μl (50 ng) of the total RNA sample was added into each tube. Then, 2 μl 
of the well-mixed Capture probeset was added to each tube and placed in the preheated 65°C 
thermal cycler. All the sample mixes were incubated for 16 hours at 65°C for completion of 
hybridization. The samples were then loaded into the sample hole in the cartridge and loaded 
into the NanoString nCounter SPRINT Profiler machine (NanoString). When the 
corresponding Reporter Library File (RLF) running is finished, the raw data were 
downloaded and analyzed with NanoString Software nSolver 3.0 (NanoString). mRNA 
counts were processed to account for hybridization efficiency, background noise, and sample 
content, and were normalized using the geometric mean of housekeeping genes. Fold 
changes were calculated comparing the experimental group to their appropriate controls. 
Heat map was generated by MeV software.
Statistical analysis
The means of two groups were compared with nonpaired two-tailed Student’s t test. To 
compare the means of more than two groups, one-way ANOVA with Tukey multiple 
comparison test was performed. All statistical analyses were performed using Prism 6 
software (GraphPad Software). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Epitope-specific manifestation of exhaustion gene signature in lung TRM cells.
WT C57BL/6 mice were infected with influenza PR8. Spleens or lungs were harvested after 
intravenous (i.v.) administration of CD45 Ab at the indicated d.p.i. (A) Expression of CD69 
and CD103 on lung NP366–374 or PA224–233 circulating memory (intravenous Ab+, TM-Circ) 
cells or TRM cells (intravenous Ab−) by flow cytometry at 40 d.p.i. (n=4). (B and C) 
Transcriptional profiles of NP366–374 and PA224–233 TRM cells were determined by RNA-seq 
at 42 d.p.i. (pooled from 16 mice). (B) Differential gene expression between NP366–374 TRM 
cells and PA224–233 TRM cells. FPKM, fragments per kilobase million. (C) GSEA showing 
positive enrichment in NP366–374 TRM cells of the genes up-regulated in exhausted CD8+ T 
cells (top) or showing negative enrichment in NP366–374 TRM cells of the genes down-
regulated in exhausted CD8+ T cells (bottom). NES, normalized enrichment score. (D and 
E) Expression of immune-related genes in NP366–374 (NP) or PA224–233 (PA) lung effector 
(TE-LUNG) and TRM cells, and spleen effector (TE-SPL) and memory (TM-SPL) cells were 
determined by NanoString at 8 (effector) or 38 (memory) d.p.i. (pooled from 4 to 12 mice 
per group). (D) Heat map representing expression levels of 560 immune-associated genes. 
(E) Heat map representing expression levels of exhaustion-associated genes.
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Fig. 2. Exhausted-like TRM cells coexhibit exhausted and memory T cell features.
(A to G) WT C57BL/6 mice were infected with influenza PR8. Spleens and lungs were 
harvested after intravenous administration of CD45 Ab at the indicated d.p.i. (A) PD-1 
expression levels [mean fluorescence intensity (MFI)] on intravenous Ab− lung NP366–374 or 
PA224–233 T cells were assessed by flow cytometry at the indicated d.p.i. (B) Expression of 
inhibitory receptors on lung NP366–374 or PA224–233 TRM cells was assessed by flow 
cytometry at 40 d.p.i. (C) Total numbers of inhibitory receptors expressed on lung NP366–374 
or PA224–233 TRM cells were assessed by flow cytometry at 40 d.p.i. (D and E) IFN-γ and 
TNF-α production by TRM cells was assessed by flow cytometry after ex vivo stimulation 
with the NP366–374 or PA224–233 peptide at 40d.p.i. (D) Representative plots of tetramer 
(Tet), IFN-γ, and TNF-α staining in lung-resident (intravenous Ab−) CD8+ cells. (E) 
Frequencies of IFN-γ+ TNF-α+ cells were normalized to the frequencies of tetramer+ TRM 
cells in resident CD8+ cells. Percentages of IFN-γ+ TNF-α+ cells in tetramer+ TRM cells 
were assessed. (F) NP366–374 or PA224–233 TRM cell TCF-1 and CD127 expression was 
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assessed by flow cytometry at 42 d.p.i. (G) Expression of CD8+ memory-associated genes in 
lung effector (TE-LUNG) or TRM cells, and spleen effector (TE-SPL) or memory (TM-SPL) 
cells was determined by NanoString at 8 or 38 d.p.i. (H and I) Tgfbr2fl/fl or Tgfbr2Δdlck 
mice were infected with influenza PR8. Spleens and lungs were harvested after intravenous 
administration of CD45 Ab at 42 d.p.i. (H) Representative flow cytometry plots. (I) 
Frequencies of NP366–374 or PA224–233 TRM and TM-SPL cells. (J) WT C57BL/6 mice were 
infected with influenza PR8, treated with FTY720 (39 to 41 d.p.i.), and then rechallenged 
with influenza X31 at 40 d.p.i. KI-67 expression in NP366–374 or PA224–233 TRM cells was 
assessed by flow cytometry before and 2 days after rechallenge. Representative of two to 
three experiments (n=2 to 7) except (G). Data are mean ± SD; ns, not significant. *P < 0.05, 
**P < 0.01, ****P < 0.0001, unpaired two-tailed t test.
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Fig. 3. TCR signaling is required for exhausted-like TRM cell formation and maintenance.
(A) Nur77-GFP mice were infected with influenza PR8. Spleens and lungs were harvested 
after intravenous administration of CD45 Ab. Green fluorescent protein (GFP) expression in 
TRM cells, lung-circulating memory (TM-Circ, intravenous Ab+), and TM-SPL cells was 
assessed by flow cytometry at 40 d.p.i. (B to D) Nur77-GFP mice were infected with 
influenza PR8 and received vehicle or FTY720 daily starting at 21 d.p.i. Mice were 
euthanized after intravenous administration of CD45 Ab at 40 d.p.i. (B) Schematic of 
experimental design (top) and representative flow cytometry plots of Nur77-GFP expression 
in NP366–374 or PA224–233 TRM cells. (C) Quantification of percentages of Nur77-GFP+ cells 
in NP366–374 or PA224–233 TRM cells after vehicle or FTY720 treatment. (D) PD-1, TIM-3, 
CD69, or CD103 expression on NP366–374 or PA224–233 TRM cells after vehicle or FTY720 
treatment was assessed by flow cytometry. (E and F) Thy1.1+ C57BL/6 WT and Thy1.2+ 
Nr4a1−/− (Nur77) mixed bone marrow (BM) chimeric mice were infected with influenza 
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PR8. Spleens and lungs were harvested after intravenous administration of CD45 Ab at 40 
d.p.i. (E) PD-1 expression on NP366–374 or PA224–233 TRM cells was determined by flow 
cytometry. (F) Representative plots (left) and percentages (right) of NP366–374 or PA224–233 
TRM cells in Thy1.1+ WT or Thy1.2+ Nr4a1−/−-resident CD8+ T cells. Representative of two 
to three experiments (n = 3 to 5). Data are mean ± SD; ns, not significant. *P < 0.05, **P < 
0.01, unpaired two-tailed t test.
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Fig. 4. Persistent TCR–pMHC-I signaling drives the formation and maintenance of exhausted-
like TRM cells.
H2dbfl/fl (Ctl) and H2dbΔUbc-creERT2 (KO) mice were infected with influenza PR8 and then 
treated with tamoxifen starting at 22 d.p.i. Spleens and lungs were harvested after 
intravenous administration of CD45 Ab at 42 d.p.i. (A) Schematic of the experimental 
design. (B) Average PD-1 or TIM-3 expression levels (MFI) on NP366–374 TRM cells 
evaluated by flow cytometry. (C) Average PD-1 or TIM-3 expression levels (MFI) on 
PA224–233 TRM cells evaluated by flow cytometry. (D) Representative plots and average 
frequencies of TRM cells (top) or TM-SPL cells (bottom) in lung-resident or splenic CD8+ T 
cells, respectively. (E) Cell numbers of NP366–374 or PA224–233 TRM cells. (F) 
Representative plot of CD103 expression on NP366–374 TRM cells. (G) Average CD103 
expression levels (MFI) on NP366–374 or PA224–233 TRM cells were evaluated by flow 
cytometry. Representative of three experiments (n=4 mice per group). Data are mean ± SD; 
ns, not significant. *P < 0.05, **P < 0.01, unpaired two-tailed t test.
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Fig. 5. B7 blockade diminishes exhausted-like TRM cell maintenance.
(A) WT mice were infected with influenza PR8. CD28 gene expression in NP366–374 or 
PA224–233 TRM cells or spleen memory T cells was determined by NanoString at 38 d.p.i. 
(B) WT mice were infected with influenza PR8. CD28 expression levels (MFI) on TRM cells 
were assessed by flow cytometry at 42 d.p.i. (C to F) WT mice were infected with influenza 
PR8 and B7 costimulation was blocked through the administration of α-B7.1 plus α-B7.2 at 
21 d.p.i. Spleens or lungs were harvested after intravenous administration of CD45 Ab at 42 
d.p.i. (C) Schematic of experimental design and PD-1 expression levels (MFI) on TRM cells. 
(D) Frequencies of NP366–374 or PA224–233 TRM cells in total lung-resident (intravenous Ab
−) CD8+ T cells. (E) Cell numbers of NP366–374 or PA224–233 TRM cells. (F) Representative 
plots (left) and frequencies (right) of active caspase-3/7+ cells in NP366–374 or PA224–233 
TRM cells. (G) WT mice were infected with influenza PR8 with or without B7 blockade at 
21 d.p.i. and then rechallenged with X31 (1.2 × 104 pfu) at 42 d.p.i. in the presence of 
FTY720. Percentages of original weight after rechallenge were assessed daily. 
Representative of two to three experiments except (A) (n = 3 to 4 mice per group). Data are 
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mean ± SD; ns, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-tailed t 
test.
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Fig. 6. PD-L1 blockade rejuvenates exhausted-like TRM cells.
(A to G) WT mice were infected with influenza PR8 and received control IgG (Ctl) or a-PD-
L1 from 21 to 37 d.p.i. Spleens and lungs were harvested after intravenous administration of 
CD45 Ab at the indicated d.p.i. (A) Experimental design and representative plots of 
NP366–37 or PA224–233 TRM cells at 40 or 60 d.p.i. (B) Frequencies of NP366–374 or 
PA224–233 TRM cells in total resident (intravenous Ab−) CD8+ T cells at 40 or 60 d.p.i. (C) 
Cell numbers of NP366–374 or PA224–233 TRM cells at 40 or 60 d.p.i. (D) Frequencies of 
active caspase-3/7+ cells in NP366–374 TRM cells at 35 d.p.i. (E) IFN-γ and TNF-α 
production by TRM cells was determined after ex vivo NP366–374 peptide stimulation at 40 
d.p.i. Left panel, representative plots. Right panel, average frequencies of IFN-γ and TNF-α 
double-positive cells with or without PD-L1 blockade. (F and G) CD103 expression on 
NP366–374 lung TRM cells was determined at 40 d.p.i. Representative plots (F) and 
frequenciesof CD103+ cells (G, left) or CD103 expression levels (MFI) (G, right) in 
NP366–374 TRM cells. (H and I) WT mice were infected with influenza PR8 and received 
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control Ab, α-PD-L1, and/or α-B7 as indicated starting at 21 d.p.i. Lungs were harvested 
after intravenous administration of CD45 Ab at 40 d.p.i. (H) Representative plots and 
percentages of TRM cells in lung-resident (intravenous Ab−) CD8+ T cells. (I) CD103 
expression levels (MFI) on TRM cells were determined by flow cytometry. Representative of 
two to four experiments (n = 3 to 6). Mean ± SD; ns, not significant. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001 unpaired two-tailed t test or one-way analysis of variance 
(ANOVA) with Tukey multiple comparison test.
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Fig. 7. TRM cell exhaustion balances protective immunity and fibrotic sequelae.
(A) WT mice were infected with influenza PR8 and received control IgG (Ctl) or α-PD-L1 
from 21 to 37 d.p.i. Mice were rechallenged with influenza X31 (2.4 × 104 pfu) in the 
presence of FTY720 at 42 d.p.i. Percentages of original weight were determined daily after 
rechallenge. (B to D) WT mice were infected with influenza PR8 and received control IgG 
(Ctl) or α-PD-L1 from 21 to 37 d.p.i. Lung pathology and hydroxyproline levels were 
determined at 60 d.p.i. (B) Hematoxylin and eosin (H&E) and Masson’s trichrome C 
staining of lung sections. (C) Hydroxyproline levels (micrograms per milligram of lung 
tissue) of the lungs. (D) Hydroxyproline levels of the lungs from mice received control Ab, 
α-PD-L1, or α-PD-L1 plus α-CD8 (CD8 depletion). (E and F) CD8, PD-1, and CD103 
staining was performed on lung sections from control (n = 10) or patients with IPF (n = 10). 
(E) Representative of CD8, PD-1, and CD103 staining. Blue, DAPI (4',6-diamidino-2-
phenylindole). (F) Frequencies of CD8+ cells, CD8+ CD103+, or CD8+ PD-1+ cells in DAPI
+ cells of control or IPF lungs. (A to D) Representative of two to five experiments (n = 3 to 
6). Mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-tailed t test.
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